StockIQ.techBoston Scientific Corporation (BSX) Stock Analysis
Free AI-powered analysis and research for Boston Scientific Corporation stock
Sector: Healthcare
BSX snapshot
Data as of 12 Oct 2026 close. Updated daily.
Boston Scientific Corporation scores 52/100 on StockIQ's model, which reads as mixed signals overall. The price is below its 200-day average and at 4% of its 52-week range, down 53.8% over the past year. Latest reported figures show a profit margin of 17.5%, return on equity of 15.3% and revenue growth of +7.5%.
What is driving the score
- RSI Neutral: +5
- Downtrend: -3
- MACD Bullish: +8
- Good Profit Margin (17.5%): +5
- Weak Liquidity (1.24 Current Ratio): -5
- Strong ROE (15.3%): +5
- Long-term Downtrend: -8
- Severe Underperformance (-53.8% over 1 year): -10
- Near 52-Week Low (4%): +5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full BSX report
Boston Scientific Corporation (BSX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze BSX Now →📰 Latest Update
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
Thu, October 8, 2026 at 9:15 PM UTC 4 min read
Boston Scientific (BSX) has shown resilience by advancing in value despite a broader market decline. This performance highlights the company's strong fundamentals and potential for growth, making it an attractive option for investors seeking stability in uncertain market conditions. As BSX continues to innovate and expand its product offerings, it may present opportunities for long-term gains.